rs7540214 — IFNLR1 IFNLR1 variant

IFNLR1 rs7540214 — The Psoriasis-to-Arthritis Transition Signal

Most people with psoriasis never develop joint disease. But roughly 30% do — and predicting who is at risk before joint damage begins is one of the central challenges in psoriatic disease management. The rs7540214 variant sits in the IFNLR1 gene, which encodes the interferon lambda receptor 1¹¹ interferon lambda receptor 1
Also known as IL-28Rα; partners with IL-10RB to form the type III interferon receptor complex that binds IL-28A, IL-28B, and IL-29, and it emerged from a large-scale genome-wide analysis as a genetic signal that specifically marks psoriatic arthritis risk rather than skin-only psoriasis.

The Mechanism

Type III interferons (IFN-lambdas) were long thought to act mainly at epithelial barriers — protecting the skin, gut lining, and airways against viral entry. The IFNLR1 receptor complex is expressed on epithelial cells, keratinocytes, and innate immune cells at these surfaces. But accumulating evidence shows that the type III interferon axis extends into synovial joints²² type III interferon axis extends into synovial joints
IL-28Rα is expressed on synovial fibroblasts and macrophages; joint fibroblasts release IL-29 in response to innate immune stimuli: fibroblasts lining the joint cavity express IFNLR1, respond to IL-29, and in turn amplify the joint inflammatory cascade.

The biological consequences of excess IL-29/IFNLR1 signaling in joint tissue are well-characterized. IL-29 stimulates synovial fibroblasts to produce IL-6, IL-8, and MMP-3³³ stimulates synovial fibroblasts to produce IL-6, IL-8, and MMP-3
Matrix metalloproteinase-3 degrades extracellular matrix components, contributing to cartilage destruction and to upregulate RANKL expression via ERK, p38, and JNK MAPK pathways⁴⁴ upregulate RANKL expression via ERK, p38, and JNK MAPK pathways
RANKL (receptor activator of NF-κB ligand) drives osteoclast differentiation and is the direct molecular mediator of bone erosion in inflammatory arthritis. It also enhances TLR4-mediated production of TNF-α⁵⁵ enhances TLR4-mediated production of TNF-α
Via NF-κB pathway activation, creating a feed-forward loop between innate immune sensing and interferon signaling. Within the joint cavity, intra-articular granzyme M triggers IL-29 release from fibroblasts⁶⁶ intra-articular granzyme M triggers IL-29 release from fibroblasts
GrM levels are elevated in RA synovial fluid and correlate with IL-29; purified GrM stimulates IL-29 secretion in vitro, providing an amplification loop specific to inflamed joints.

The rs7540214 T allele tags a haplotype that may alter IFNLR1 expression or receptor complex activity in joint-resident cells. A 2025 Mendelian randomization study found that elevated IFNLR1 protein levels are causally associated with PsA risk⁷⁷ elevated IFNLR1 protein levels are causally associated with PsA risk
IFNLR1 expression is significantly upregulated by 48-hour co-stimulation with IL-17A and IL-23 — the cytokines that dominate psoriatic disease pathogenesis, and that IFNLR1 is among the few proteins showing a positive causal association in proteome-wide MR.

The Evidence

The primary genetic evidence comes from a 2015 GWAS meta-analysis by Stuart et al.⁸⁸ 2015 GWAS meta-analysis by Stuart et al.
3,061 PsA cases, 3,110 cutaneous-only psoriasis cases, and 13,670 controls of European descent across six discovery studies that systematically compared the genetic architectures of psoriatic arthritis and skin-limited psoriasis. Among ten loci achieving genome-wide significance for PsA, IFNLR1 was specifically flagged as a novel association that had not previously reached genome-wide significance — and critically, as a locus differentiated between PsA and cutaneous-only disease. This PsA-specificity is the key clinical interpretation: the variant does not simply tag psoriasis susceptibility in general, but marks the subset of psoriasis patients at elevated risk for joint involvement.

Beyond direct genetic association, the IFNLR1-PsA link has biological support from multiple mechanistic streams. IFNLR1 variants (including rs4649203 in the same gene) have been associated with rheumatoid arthritis and systemic lupus erythematosus⁹⁹ rheumatoid arthritis and systemic lupus erythematosus
rs4649203-G associated with SLE and RA occurrence, with disease sub-phenotype effects on serositis, anemia, vasculitis, and nodule formation, establishing that IFNLR1 genetic variation shapes broad inflammatory arthritis risk, not just psoriatic disease.

Practical Implications

Carrying the T allele — either as CT heterozygous or TT homozygous — does not cause arthritis. The large majority of T allele carriers with psoriasis will not develop joint disease. However, this variant provides meaningful prior probability information that can sharpen monitoring decisions. For someone already diagnosed with psoriasis, an rs7540214 T allele should prompt attention to joint symptoms that might otherwise be attributed to mechanical causes: morning stiffness lasting more than 30 minutes, pain in distal interphalangeal joints (especially with nail changes), lower back pain with inflammatory features (worse at rest, improved with movement), or dactylitis (sausage finger/toe).

Biologics targeting the IL-23/IL-17 axis — the same cytokines that upregulate IFNLR1 expression — form the cornerstone of PsA treatment. This genetic background may be one reason why IL-23 blockade is particularly effective in PsA: suppressing IL-23 reduces the co-stimulatory signal that drives IFNLR1 upregulation in joint fibroblasts.

Interactions

IFNLR1 signaling intersects with the broader type I interferon system (IFN-alpha/beta) that is amplified by IRF5 variants (rs10488631). Both type I and type III interferons drive overlapping proinflammatory gene programs in synovial tissue. An individual carrying risk alleles at both IRF5 and IFNLR1 would have amplification at two distinct nodes of the interferon axis — a combination that has not been formally studied in PsA but warrants investigation given the additive effects documented for IRF5 variants in other autoimmune conditions.

The IFNLR1 locus has also been fine-mapped at the chromatin level: a nearby variant (rs10794648) at this locus was linked to GRHL3 through chromatin looping in dermatological risk loci studies, suggesting that the functional impact may extend beyond IFNLR1 itself to regulatory elements controlling epithelial barrier gene expression.